Romidepsin-Bendamustine Combination for Relapsed/Refractory T Cell Lymphoma.
Bendamustine
Romidepsin
T cell lymphoma
Journal
Acta haematologica
ISSN: 1421-9662
Titre abrégé: Acta Haematol
Pays: Switzerland
ID NLM: 0141053
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
11
2018
accepted:
12
02
2019
pubmed:
4
4
2019
medline:
30
10
2019
entrez:
4
4
2019
Statut:
ppublish
Résumé
The treatment of relapsed/refractory (R/R) peripheral T cell lymphoma (PTCL) is limited to a few agents. Romidepsin, a histone deacetylase inhibitor, was approved for PTCL treatment as a single agent in the R/R setting, yet with partial efficacy. Several attempts to combine romidepsin with other chemotherapy regimens have been reported, however, with significant toxicity. To study the romidepsin-bendamustine combination in PTCL in an attempt to maximize efficacy while minimizing toxicity. We report on a series of 7 heavily pretreated PTCL patients (2-5 previous lines of therapy) treated with a romidepsin-bendamustine combination. Four patients were not previously exposed to either drug. Of these, 2 achieved complete remission. Interestingly, 1 patient continued treatment with a prolonged progression-free survival of more than 4 years. Toxicity was minimal and no treatment-related deaths or discontinuation were noted. Significant nausea and vomiting were reported in over 50% of patients. Hematological toxicity was mild and lower than that reported for other romidepsin-chemotherapy combinations and was correlated with bone marrow involvement by lymphoma. Although reporting a small number of patients, our data suggest that the combination of romidepsin and bendamustine may be a feasible therapeutic option in R/R PTCL patients and merits further study.
Sections du résumé
BACKGROUND
The treatment of relapsed/refractory (R/R) peripheral T cell lymphoma (PTCL) is limited to a few agents. Romidepsin, a histone deacetylase inhibitor, was approved for PTCL treatment as a single agent in the R/R setting, yet with partial efficacy. Several attempts to combine romidepsin with other chemotherapy regimens have been reported, however, with significant toxicity.
OBJECTIVES
To study the romidepsin-bendamustine combination in PTCL in an attempt to maximize efficacy while minimizing toxicity.
METHODS
We report on a series of 7 heavily pretreated PTCL patients (2-5 previous lines of therapy) treated with a romidepsin-bendamustine combination.
RESULTS
Four patients were not previously exposed to either drug. Of these, 2 achieved complete remission. Interestingly, 1 patient continued treatment with a prolonged progression-free survival of more than 4 years. Toxicity was minimal and no treatment-related deaths or discontinuation were noted. Significant nausea and vomiting were reported in over 50% of patients. Hematological toxicity was mild and lower than that reported for other romidepsin-chemotherapy combinations and was correlated with bone marrow involvement by lymphoma.
CONCLUSIONS
Although reporting a small number of patients, our data suggest that the combination of romidepsin and bendamustine may be a feasible therapeutic option in R/R PTCL patients and merits further study.
Identifiants
pubmed: 30943470
pii: 000498905
doi: 10.1159/000498905
doi:
Substances chimiques
Depsipeptides
0
Bendamustine Hydrochloride
981Y8SX18M
romidepsin
CX3T89XQBK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
216-221Informations de copyright
© 2019 S. Karger AG, Basel.